Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzyl Carbamimidothioate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 1.00 |
| ▸ | NOS1 | P29475 | 4/20 | 0.95 |
| ▸ | NOS3 | P29474 | 1/20 | 0.95 |
| ▸ | NOS2 | P35228 | 1/20 | 0.95 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.73 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzyl Carbamimidothioate SCHEMBL974745 | 0.98 | IDO1 (1.00) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL14576763 | 0.95 | IDO1 (1.00) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL28084166 | 0.95 | IDO1 (0.95) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL4911682 | 0.95 | IDO1 (1.00) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL28084165 | 0.93 | IDO1 (0.91) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL27962431 | 0.93 | IDO1 (0.91) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL9507886 | 0.91 | IDO1 (0.88) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL27476627 | 0.90 | IDO1 (0.84) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL14714919 | 0.88 | IDO1 (0.81) | IDO1NOS1NOS3NOS2SLC11A2 | |
| Benzyl Carbamimidothioate SCHEMBL11527781 | 0.88 | IDO1 (0.81) | IDO1NOS1NOS3NOS2SLC11A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122054814-A | S-benzyl isothiourea hydrochloride modified carbon-based CsPbI3Perovskite battery and preparation thereof | 晶鹏能源(北京)有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | claimed |
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO (US) | 2026-02-19 | — | — | US | claimed |
| CN-120195048-A | Rapid detection method for diglyceride content in oil sample | 西北农林科技大学 | 2025-06-24 | — | — | CN | claimed |
| CN-119192087-A | Chemical synthesis method of ergothioneine | 镇江卡博医药科技有限公司 | 2024-12-27 | — | — | CN | claimed |
| WO-2024214107-A1 | AN IMPROVED PROCESS FOR PREPARING BENZYL MERCAPTAN | PHARVINEX CHEMPHARM PVT. LTD. (IN) | 2024-10-17 | — | — | WO | claimed |
| CN-117568805-A | CO inhibition 2 Corrosion inhibitor for corrosion and preparation method and application thereof | 西安石油大学 | 2024-02-20 | — | — | CN | claimed |
| US-20230398077-A1 | SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-14 | — | — | US | claimed |
| EP-4237091-A1 | A SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2023081514-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-11 | — | — | WO | claimed |
| WO-2022094132-A1 | A SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-05 | — | — | WO | claimed |
| CN-108529732-B | Method for purifying iron-containing protein wastewater based on ionic liquid | 河南师范大学 | 2021-05-25 | — | — | CN | claimed |
| US-20210094995-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO | 2021-04-01 | — | — | US | claimed |
| EP-3762407-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | The University of Chicago (US) | 2021-01-13 | — | — | EP | claimed |
| US-20200123228-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES | THE UNIVERSITY OF CHICAGO | 2020-04-23 | — | — | US | claimed |
| EP-3612209-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES | The University of Chicago (US) | 2020-02-26 | — | — | EP | claimed |
| WO-2019173289-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | THE UNIVERSITY OF CHICAGO (US) | 2019-09-12 | — | — | WO | claimed |
| WO-2018195386-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES | THE UNIVERSITY OF CHICAGO (US) | 2018-10-25 | — | — | WO | claimed |
| CN-105017569-A | Degradable composite tourist commodity packaging film and preparation method thereof | JILIN TECHNOLOGY COLLEGE OF ELECTRONIC INFORMATION | 2015-11-04 | — | — | CN | claimed |
| CN-103896859-A | Process for synthesizing cytosine | ZHEJIANG XIANFENG TECHNOLOGIES CO LTD | 2014-07-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049115-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO CYTOKINES | FN1, MATR3, COL14A1 | IDO1 2219/4885NOS1 1933/4885NOS3 1435/4885 |
| US-20260069538-A1 | CXCR4 ANTAGONIST LOADED LIPOSOMES AND SILICASOMES | CXCL12, CXCR4, CXCR5 | IDO1 621/4885NOS1 2971/4885NOS3 3921/4885 |
| US-20230398077-A1 | SILICASOME NANOCARRIER FOR METAL-BASED DRUG DELIVERY | CD47, SGMS1, ABCC1 | IDO1 3107/4885NOS1 2476/4885NOS3 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.